GSK stops Keytruda combo trials after ICOS drug falls short

GSK stops Keytruda combo trials after ICOS drug falls short

Source: 
Fierce Biotech
snippet: 

GlaxoSmithKline has stopped two clinical trials of feladilimab in combination with Keytruda after an interim review. Other studies of the ICOS agonist are continuing, but the future of the program is now in doubt.